Anemia frequently occurs in gynecologic malignancy patients undergoing adjuvant therapy，with iron-deficiency anemia （IDA） being the most prevalent. Anemia reduces patients' tolerance to treatment，leading to therapy delays，dose reductions，or even discontinuation. This may result in chemotherapy resistance and decreased radiotherapy sensitivity. Correcting anemia can improve prognosis，so standardized anemia management is essential. Common therapeutic approaches include iron supplementation，erythropoiesis-stimulating agents （ESAs），and blood transfusions. Among these，third-generation intravenous iron preparations have emerged as a new option in the anemia management in adjuvant therapy for patients with gynecological malignancies due to their rapid iron repletion，reduced transfusion risks，and the convenience of single-dose administration.